rosiglitazone has been researched along with Di Guglielmo Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coyle, AT; Kinsella, BT | 1 |
| Hishinuma, T; Mizugaki, M; Yamazaki, T | 1 |
2 other study(ies) available for rosiglitazone and Di Guglielmo Disease
| Article | Year |
|---|---|
Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells.
Topics: Cell Line; Cell Line, Tumor; Chromans; Genes, Reporter; Humans; Leukemia, Erythroblastic, Acute; Luciferases; PPAR gamma; Promoter Regions, Genetic; Prostaglandin D2; Protein Isoforms; Receptors, Thromboxane A2, Prostaglandin H2; Retinoid X Receptor alpha; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription Factor AP-1; Transcription, Genetic; Troglitazone | 2006 |
Troglitazone has a reducing effect on thromboxane production.
Topics: Arachidonic Acid; Blood Platelets; Chromans; Diabetes Mellitus, Type 2; Fibrinolytic Agents; Gas Chromatography-Mass Spectrometry; Humans; Leukemia, Erythroblastic, Acute; Rosiglitazone; Thiazoles; Thiazolidinediones; Thromboxane A2; Troglitazone; Tumor Cells, Cultured; Vitamin E | 2000 |